BMS/Bluebird Ready Abecma, First BCMA-Targeting CAR-T, For Initial Patients
REMS-Required Training And Certification Under Way
Idecabtagene vicleucel for fifth-line multiple myeloma lags GSK’s BCMA-targeting ADC Blenrep, but it is months ahead of J&J/Legend’s CAR-T. Abecma is BMS’s second CAR-T approval this year.
